Given the overexpression of BET proteins in cancer, previous studies have shown the promise of targeting BET proteins as an intervention strategy in hematologic malignancies, breast cancer [21], prostate cancer [22], etc. Consistently, one study showed that the pan-BET inhibitor (pan-BETi) JQ-1 reduces liver fibrosis [23], or liver tumor burden in a mouse model of non-alcoholic steatohepatitis (NASH)-HCC [24]. Here, DNER is linked to prostate carcinoma.